Skip to main content

Table 2 Multivariate analysis of BCSS in the whole and matched cohorts

From: Is surgical axillary staging necessary in women with T1 breast cancer who are treated with breast-conserving therapy?

Variable Whole cohort Matched cohort
HR (95% CI) P HR (95% CI) P
Diagnosis year
 2000–2003 Ref.   Ref.  
 2004–2008 0.76 (0.72–0.80) < 0.001 0.69 (0.56–0.86) 0.001
 2009–2012 0.63 (0.57–0.69) < 0.001 0.64 (0.45–0.92) 0.014
Race
 NHW Ref.   Ref.  
 NHB 1.51 (1.39–1.64) < 0.001 1.27 (0.91–1.78) 0.157
 NHAIAN 1.42 (1.01–1.99) 0.047 4.73 (1.16–19.27) 0.030
 NHAPI 0.89 (0.79–0.99) 0.047 1.29 (0.83–2.00) 0.266
 Hispanic 1.11 (1.01–1.22) 0.036 0.94 (0.61–1.44) 0.760
 Unknown 0.45 (0.20–1.01) 0.050 0.00 (0.00–12.40) 0.925
Marital status
 Married Ref.   Ref.  
 Single 1.17 (1.08–1.27) < 0.001 1.10 (0.78–1.57) 0.571
 Widowed 1.26 (1.17–1.36) < 0.001 1.25 (1.01–1.55) 0.045
 Divorced 1.23 (1.13–1.33) < 0.001 1.15 (0.82–1.62) 0.416
 Unknown 1.14 (0.98–1.32) 0.095 0.97 (0.54–1.74) 0.914
Age (years)
 18–49 Ref.   Ref.  
 50–64 0.96 (0.89–1.03) 0.200 0.69 (0.48–0.99) 0.042
 65–79 1.69 (1.56–1.83) < 0.001 1.13 (0.81–1.57) 0.466
 80– 3.08 (2.74–3.46) < 0.001 1.72 (1.23–2.41) 0.001
T stage
 T1mic Ref.   Ref.  
 T1a 1.29 (0.76–1.68) 0.065 1.35 (0.76–2.40) 0.309
 T1b 1.78 (1.14–2.28) < 0.001 1.94 (1.14–3.33) 0.015
 T1c 2.93 (2.15–3.73) < 0.001 3.62 (2.15–6.10) < 0.001
Histological type
 Ductal Ref.   Ref.  
 Lobular 0.94 (0.87–1.01) 0.077 0.87 (0.67–1.13) 0.295
 Favorable 0.61 (0.52–0.72) < 0.001 0.99 (0.69–1.42) 0.966
 Others 0.69 (0.57–0.83) < 0.001 0.93 (0.46–1.88) 0.840
Grade
 I Ref.   Ref.  
 II 1.75 (1.62–1.90) < 0.001 1.62 (1.27–2.06) < 0.001
 III 2.68 (2.45–2.93) < 0.001 2.50 (1.89–3.32) < 0.001
 Unknown 1.81 (1.58–2.09) < 0.001 1.32 (0.88–2.00) 0.180
ER
 Negative Ref.   Ref.  
 Positive 0.73 (0.67–0.80) < 0.001 0.67 (0.48–0.92) 0.013
 Unknown 0.69 (0.57–0.85) < 0.001 0.38 (0.19–0.75) 0.006
PR
 Negative Ref.   Ref.  
 Positive 0.74 (0.69–0.79) < 0.001 0.74 (0.57–0.97) 0.027
 Unknown 1.00 (0.83–1.20) 0.998 1.48 (0.80–2.72) 0.213
Chemotherapy
 No Ref.   Ref.  
 Yes 1.49 (1.39–1.58) < 0.001 1.29 (0.94–1.77) 0.115
Surgical axillary staging
 No Ref.   Ref.  
 Yes 0.68 (0.60–0.76) < 0.001 0.70 (0.59–0.83) < 0.001
  1. BCSS breast cancer-specific survival, HR hazard ratios, CI confidence intervals, NHW non-Hispanic white, NHB non-Hispanic black, NHAIAN non-Hispanic American Indian/Alaska native, NHAPI non-Hispanic Asian or Pacific Islander, ER estrogen receptor, PR progesterone receptor